Africa: Gavi and Global Fund Statement On Malaria Vaccine Recommendations

[Global Fund] Geneva -Today's recommendations by two advisory bodies to the World Health Organization, the Strategic Advisory Group of Experts on Immunization (SAGE) and the Malaria Policy Advisory Committee (MPAC), for use of the RTS,S malaria vaccine are a step toward making the vaccine available in countries with a heavy malaria burden as well as an opportunity to assess its likely real world impact.
Source: AllAfrica News: Malaria - Category: Infectious Diseases Source Type: news

Related Links:

[allAfrica] Dakar -An African scientific conference this week was "a platform for this young generation to express their views about how they perceive the future of science in Africa. We will leave here with new motivations and more opportunities." - Aminata Kone
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
[allAfrica] "There is still a huge amount of effort in trying to develop malaria vaccines."
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Plasmodium falciparum merozoite surface protein-1 (PfMSP-1) and -2 (PfMSP-2) are major blood-stage vaccine candidate antigens. Understanding the genetic diversity of the genes, pfmsp-1 and pfmsp-2, is important f...
Source: Malaria Journal - Category: Infectious Diseases Authors: Tags: Research Source Type: research
Authors: LoVerde PT Abstract Schistosomiasis is a major cause of morbidity in the world; it is second only to malaria as a major infectious disease. Globally, it is estimated that the disease affects over 250 million people in 78 countries of the world and is responsible for some 280,000 deaths each year. The three major schistosomes infecting humans are Schistosoma mansoni, S. japonicum, and S. haematobium. This chapter covers a wide range of aspects of schistosomiasis, including basic biology of the parasites, epidemiology, immunopathology, treatment, control, vaccines, and genomics/proteomics. In this chapt...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Publication date: Available online 9 July 2019Source: The LancetAuthor(s): Lode Schuerman
Source: The Lancet - Category: General Medicine Source Type: research
Condition:   Malaria, Vivax Intervention:   Biological: ChAd63 PvDBP and MVA PvDBP Sponsor:   University of Oxford Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Advances in medical technology continue apace, with sophisticated new medical devices and therapies becoming available on an ongoing basis. However, medical technology often comes at a premium, and for low-resource regions sometimes even relatively b...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiology Critical Care Diagnostics Emergency Medicine ENT Exclusive Genetics Materials Pathology Public Health Source Type: blogs
Advice comes as measles outbreaks strike Europe Related items fromOnMedica Rapid rise in flu consultations putting strain on GPs Parental confidence in immunisation programme ‘very high’ Doctors can help overcome ‘vaccine hesitancy’ Repeated flu jabs reduce hospital admissions Africans in the UK most likely to acquire malaria
Source: OnMedica Latest News - Category: UK Health Source Type: news
During pregnancy, Plasmodium falciparum-infected erythrocytes (IE) accumulate in the intervillous spaces of the placenta by binding to chondroitin sulfate A (CSA) and elicit inflammatory responses that are associated with poor pregnancy outcomes. Primigravidae lack immunity to IE that sequester in the placenta and thus are susceptible to placental malaria (PM). Women become resistant to PM over successive pregnancies as antibodies to placental IE are acquired. Here, we assayed plasma collected at delivery from Malian and Tanzanian women of different parities for total antibody levels against recombinant VAR2CSA antigens (F...
Source: Infection and Immunity - Category: Infectious Diseases Authors: Tags: Microbial Immunity and Vaccines Source Type: research
Most vaccines for diseases in low- and middle-income countries fail to be developed because of weak or absent market incentives. Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable investment and a new sustainable model of vaccine development involving close collaborations between public and private sectors.
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Perspectives Source Type: research
More News: African Health | Health | Infectious Diseases | International Medicine & Public Health | Malaria | Malaria Vaccine | Vaccines | WHO